CTOR.US Citius Oncology, Inc.

Healthcare Life Sciences Tools & Services USA Stocks
0.5738 USD
Close of Nov 14, 2026
0.4910 1.83
Market cap
USD 60.7M
P/E
-
P/B
1.37x
ROE
-135.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is CTOR.US undervalued?

Graham number

The Graham number of Citius Oncology, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Citius Oncology, Inc. fundamental analysis

No fundamental analysis for Citius Oncology, Inc. yet.

Citius Oncology, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Citius Oncology, Inc.

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Full company profile